Search results
Triple semicircular canal occlusion and endolymphatic sac decompression may alleviate vertigo
Medical Xpress· 6 hours agoTriple semicircular canal occlusion combined with endolymphatic sac decompression (ESD) may be an...
FLI1 promotes IFN-γ-induced kynurenine production to impair anti-tumor immunity - Nature...
Nature· 7 days agoThe immunosuppressive tumour microenvironment in Nasopharyngeal carcinoma (NPC) is a cause of low efficacy of immunotherapies in these tumours. In this study, the authors delineate a FLI1-mediated ...
Tomato skin secrets unlocked: a genetic leap for e | Newswise
Newswise· 2 days agoCultivation of the tomato, a dietary staple, is often marred by the ravages of decay and the...
Randomized Trial Finds Circumcised Men Are Less Likely to Get HIV
ScienceAlert via Yahoo News· 1 day agoA new randomized controlled trial adds weight to claims that circumcision may reduce the risk of infection by the human immunodeficiency virus (HIV) among men who have sex with men. While observational ...
Novel Bispecific in EGFR-Mutant Lung Cancer Boosts PFS After Targeted Agents
MedPage Today· 5 days agoChina-based trial may present a hurdle to FDA approval, however
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in...
Benzinga· 4 days agoSUZHOU, China, and ROCKVILLE, Md., June 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study...
KOIN News 6 Portland· 3 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
China-Malaysia literary collaboration unveils ecological masterpiece
China Daily· 6 days agoIn 2024, commemorating the 50th anniversary of diplomatic relations between China and Malaysia, Guangxi Normal University Press Group and Asia Think Tank Company sealed a trade agreement at ...
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on...
Morningstar· 4 days agoSeparate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46 For Subset of Patients Previously Receiving 3rd Generation EGFR-TKI: PFS Hazard Ratio of 0.48 5.